FDA OKs New Crohn’s Treatment You Can Inject at Home (WebMD)

The FDA has approved Tremfya (guselkumab) for moderate to severe Crohn’s disease, offering a convenient at-home self-injection option in addition to IV infusion. This IL-23 inhibitor is the first of its kind to also target CD64+ cells, enhancing its effectiveness. Clinical trials showed significant remission rates—up to 65% at 48 weeks—among patients who had not responded to standard treatments. Already approved for psoriasis, psoriatic arthritis, and ulcerative colitis, Tremfya now brings flexibility and new hope to Crohn’s patients through a more accessible treatment option.